Pfenex Inc. (PFNX) EPS Estimated At $-0.33

July 13, 2018 - By Theresa Judd


Analysts expect Pfenex Inc. (NYSEAMERICAN:PFNX) to report $-0.33 EPS on August, 8.They anticipate $0.19 EPS change or 36.54 % from last quarter’s $-0.52 EPS. After having $-0.47 EPS previously, Pfenex Inc.’s analysts see -29.79 % EPS growth. The stock decreased 6.14% or $0.36 during the last trading session, reaching $5.5. About 198,247 shares traded. Pfenex Inc. (NYSEAMERICAN:PFNX) has risen 42.96% since July 13, 2017 and is uptrending. It has outperformed by 30.39% the S&P500.

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company has market cap of $172.72 million. The Company’s lead product candidates include PF708, a therapeutic equivalent candidate to Forteo for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. It currently has negative earnings. The firm also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.